Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
108.41(c) 107.85(c) 106.71(c) 105.65(c) 106.7(c) Last
4 710 324 5 487 024 7 218 708 7 503 733 7 181 268 Volume
+0.62% -0.52% -1.06% -0.99% +0.99% Change
More quotes
Financials (USD)
Sales 2021 55 324 M - -
Net income 2021 15 392 M - -
Net Debt 2021 65 947 M - -
P/E ratio 2021 13,1x
Yield 2021 4,81%
Sales 2022 58 757 M - -
Net income 2022 17 207 M - -
Net Debt 2022 52 077 M - -
P/E ratio 2022 11,3x
Yield 2022 5,15%
Capitalization 188 B 188 B -
EV / Sales 2021 4,60x
EV / Sales 2022 4,09x
Nbr of Employees 47 000
Free-Float 98,4%
More Financials
Company
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.1%), Japan (2.6%),... 
Sector
Pharmaceuticals
Calendar
04/14Ex-dividend day for
More about the company
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ABBVIE INC.
05:45aHaving Trouble Getting the Covid Vaccine? Your Company Might Soon Offer It.
DJ
03/03VIVENDI : The Good Results for 2020 Confirm the -6-
DJ
03/01PRESS RELEASE  : Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Offi..
DJ
03/01PHARMARON BEIJING  : Shares Jump 3% on $120 Million Purchase of UK-Based Biomanu..
MT
02/26WARREN BUFFETT : Warren Buffett's Annual Letter Is About to Land
DJ
02/25ABBVIE  : Allergan Submits New Drug Application for Investigational Eye Disease ..
MT
02/25ABBVIE  : HUMIRA Receives FDA Approval to Treat Pediatric Patients Living with M..
AQ
02/25ABBVIE  : Allergan Seeks FDA OK of AGN-190584 in Presbyopia
DJ
02/25ABBVIE  : Allergan, an AbbVie Company, Submits New Drug Application for Investig..
PR
02/24ABBVIE  : HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients..
PR
02/24ABBVIE  : Skyrizi to Treat Psoriasis Gets Public Payer Coverage in PEI
DJ
02/24ABBVIE  : SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now ..
AQ
02/23ABBVIE  : Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical..
AQ
02/23MARKET CHATTER : Medytox Settles Trade Dispute with Evolus over Botox Product Sa..
MT
02/22Health Care Down On Defensive Bias -- Health Care Roundup
DJ
More news
News in other languages on ABBVIE INC.
03/01DGAP-NEWS  : Abivax ernennt Dr. med. Sophie Biguenet zum Chief Medical Officer
02/24EY  : 2020 anno migliore per finanziamenti a startup e scaleup italiane
02/17MÄRKTE USA/Dow auf Rekordhoch - Techwerte schwach
02/17MÄRKTE USA/Technologiewerte unter Druck - Inflationssorgen belasten
02/17MÄRKTE USA/Leichte Abgaben - US-Daten befeuern Inflationssorgen
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 119,67 $
Last Close Price 106,70 $
Spread / Highest target 31,2%
Spread / Average Target 12,2%
Spread / Lowest Target -9,09%
EPS Revisions
Managers and Directors
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.-0.42%188 420
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ELI LILLY AND COMPANY22.55%187 971
NOVARTIS AG-6.52%186 338